Press release
MDD, Anxiety and Panic Disorder Therapeutics Market Trends and Forecast 2014 – 2020 MDD, Anxiety and Panic Disorder Therapeutics Market Trends and Forecast 2014 – 2020
Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2928
Recent patent expiries did create a few bottlenecks for the market, but key players are investing in the research and development to discover novel therapeutics. Presently, cognitive-behavioral therapy (CBT) is an effective treatment for psychological disorder but it requires the support of anti-depressants in the first line of treatment, apart from other drugs. However, administering anti-depressants could trigger panic attacks in patients with bipolar disorders, which can be analyzed by mapping the patient’s family history before diagnosis.
Lack of awareness about comparable theories could prove damaging for the market. Hence, the leading producers of MDD, anxiety, and panic disorder therapeutics have been finding it difficult to penetrate underdeveloped regions as they lack adequate support of skilled medical professionals. Nevertheless, opportunities across developing and underdeveloped economies are expected to rise as their governments plan to accelerate healthcare spending.
Based on recent updates, TMR forecasts promising growth for the global MDD, anxiety, and panic disorder market. The forthcoming patent expiry of blockbuster drugs such as Eli Lilly’s Cymbalta and BMS/Otsuka’s Abilify is likely to create growth opportunities for market players. Besides this, the key market players are also looking to gain from pipeline products such as Alkermes and Forest (Actavis)/Gedeon’s ALKS-5461, Naurex’s GLYX-13, and Richter/Mitsubishi Tanabe Pharma’s cariprazine. Approval of these pipeline drugs will fuel sales prospects in the market.
Epidemiologic studies have found that a majority of individuals experiencing panic attacks are likely to experience MDD at some point. This factor boosts the chances of the co-occurrence of panic disorders. These disorders can lead to functional disability along with triggering suicidal instincts in patients. Be it the current hectic lifestyle or a prolonged family history of anxiety, the world today is witnessing more cases of MDD, anxiety, and panic disorders than ever before. This would accelerate the demand for effective diagnosis and treatment modalities to help patients not succumb to the condition.
TMR therefore forecasts that the demand for novel therapeutics will surge in response to the rising incidence of anxiety, panic disorders, and MDD. Some of the key players in the global MDD, anxiety, and panic disorder market likely to gain from the prevailing trends are Forest Laboratories, Shire Plc, Astra Zeneca Plc, Novartis AG, Eli Lilly and Company, BTG International (BTG), Janssen Pharmaceuticals, Inc. (JPI), Pfizer, Inc., H. Lundbeck A/S, and Alexza Pharmaceuticals.
Browse Research Report on Global MDD, Anxiety and Panic Disorder Therapeutics Market:
http://www.transparencymarketresearch.com/mdd-anxiety-panic-disorder-therapeutics.html
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release MDD, Anxiety and Panic Disorder Therapeutics Market Trends and Forecast 2014 – 2020 MDD, Anxiety and Panic Disorder Therapeutics Market Trends and Forecast 2014 – 2020 here
News-ID: 359554 • Views: …
More Releases from TMR - Research Reports
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during…
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the…
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016.
The global dental membrane and bone graft substitutes market is expected to…
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period.
By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment…
More Releases for MDD
Depression-MDD Drugs Market: Reviva Pharmaceuticals Holdings, H. Lundbeck, Glaxo …
The Depression-MDD Drugs Market research report offers in-depth information to acknowledge the imperative parts of the market that align demand, raw materials, and capacity; this helps make strategic decisions. In addition, the analysis provides demands for the future, besides the available opportunities for an individual. The study focuses on industry chain analysis, upstream and downstream raw material suppliers, key players, production process analysis, cost analysis, market distribution channels, and major…
Major Depressive Disorder (MDD) Market In Depth Analysis 2021 To 2059Pfizer, Gla …
Complete study of the global Major Depressive Disorder (MDD) market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Major Depressive Disorder (MDD) industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the…
U.S. Major Depressive Disorder (MDD) Market: Industry Analysis & Outlook (2018-2 …
This report is available at 10% Discount for Single user License, 20% Discount for Corporate User License till 30 September 2018. To avail discount please contact at +1-888-391-5441 / sales@marketreportsonline.com.
Major Depressive Disorder Market (MDD) is a common mental illness characterized by persistent low mood that interferes with the person’s ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression.
Place a…
Major Depressive Disorder (MDD) Treatment Market - Global Industry Analysis 2025
Major depressive disorder (MDD) also known as clinical depression is a mental health disorder which affects mood, behavior as well as appetite and sleep. The exact cause of MDD is not known, however, several factors which can increase its risk is combination of genes and stress that affects brain chemistry and reduce the ability to maintain mood stability. Imbalanced hormone, alcohol or drug abuse, certain medical conditions such as cancer…
Major Depressive Disorder (MDD) Treatment Market - Global Industry Analysis 2025
Major depressive disorder (MDD) also known as clinical depression is a mental health disorder which affects mood, behavior as well as appetite and sleep. The exact cause of MDD is not known, however, several factors which can increase its risk is combination of genes and stress that affects brain chemistry and reduce the ability to maintain mood stability. Imbalanced hormone, alcohol or drug abuse, certain medical conditions such as cancer…
Market Forecast Report on Major Depressive Disorder (MDD) Treatment, 2016-2026
Major Depressive Disorder (MDD) is one of the most common mental disorder characterized by persistent and tenacious low mood that interferes with the person’s ability to work, eat, sleep and normal activities. MDD is also referred as clinical depression, major depression, and unipolar depression or as recurrent depression. The common symptoms associated with this disorder include insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability…
